Olorinab (APD371) is a potent and selective full agonist of the cannabinoid receptor type 2 (CB2), with an EC50 of 6.2 nM for hCB2; it demonstrates significant analgesic effects in vivo, increasing paw withdrawal thresholds at doses ≥3 mg/kg (ED50 = 2.3 mg/kg) and providing up to 4 hours of analgesia after a single 10 mg/kg oral dose; its analgesic effects are highly likely mediated through CB2 receptor activation.